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1728Leukemia Lineage-Specific Chimerism Analysis
and Molecular Monitoring Improve Outcome of Donor
Lymphocyte Infusions
Darius Sairafi,1 Mats Remberger,2 Michael Uhlin,2 Per Ljungman,3
Olle Ringden,1,2 Jonas Mattsson1,2A retrospective analysis was performed of 118 patients with hematologic malignancies who received donor
lymphocyte infusions (DLIs) after allogeneic stem cell transplantation (ASCT). Treatment was either given be-
cause of hematologic relapse (n 5 44), molecular/cytogenetic relapse (n 5 52), or other causes (n 5 22).
Molecular relapsewas inmost cases based on leukemia lineage-specific chimerism analysis. Patientswith acute
leukemia and myelodysplastic syndrome showed a 3-year survival of 42% if DLI treatment was given because
of molecular relapse, compared to 16% in hematologic relapse (P\.006). In multivariate analysis, there was
a correlation between response to DLI and nonhematologic relapse (risk ratio [RR] 3.36, P5 .001), chronic
graft-versus-host disease (cGVHD) (RR5 1.51, P5.005), and late relapse (RR5 2.06, P5.017). The overall
incidences of acute GVHD (aGVHD) grades I-II and grades III-IV aGVHD were 33% and 8.5%, respectively.
Probability of cGVHD was 33%. The development of aGVHD or cGVHD did not significantly influence the
response of DLI in patients with molecular/cytogenetic relapse. However, the development of cGVHD was
significantly associated with a better response in patients with hematologic relapse because only 4 of 29
patients without cGVHD responded compared to 7 of 12 with cGVHD (P 5 .007). The development of
cGVHD increased significantly if DLIwas given.12months afterASCT (46% versus 27%, P5.04). In contrast,
time between ASCTand start of DLI treatment had no significant influence on the risk of developing aGVHD.
To conclude, monitoring of leukemia lineage-specific chimerism is of utmost importance for DLI response
after ASCT.
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Allogeneic stem cell transplantation (ACST) can
be curative and give long-termsurvival in a highpropor-
tion of patients with hematologic malignancies and
nonmalignant disorders of the immunohematopoietic
system [1,2]. The graft-versus-leukemia (GVL) effect
is of major importance for the success of ASCT in the
treatmentofmalignant disease [3].There is a strongcor-
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6/j.bbmt.2010.06.005and GVL as previously described [4,5]. Clinically,
a significant GVL effect is induced by chronic rather
than acute GVHD (cGVHD, aGVHD) [6]. Despite
this, relapse of the underlying malignant disease
remains the major obstacle after ASCT in patients
with leukemia.
Augmentation of the GVL effect by either with-
drawal of immunosuppression and/or donor lympho-
cyte infusion (DLI) is one major treatment strategy
for relapse after ASCT [7]. T cells play a major role
in inducing GVL effects after ASCT, and patients
who receive T cell-depleted grafts have an increased
risk of relapse after ASCT [4,8].
The effect of DLI for treating relapse of the under-
lying disease has been substantiated in several studies
[9,10]. However, T cells are also the major cause of
GVHD, which can be detrimental to the patient
[11].The likelihood of developing GVHD after DLI
depends on several factors such as the cell dose and
the time interval between ASCT and DLI [12,13].
DLIs are used in nearly all malignant diseases for
which ASCT is performed, but with highly variable
efficacy. The best results have been obtained in patients
Table 1. Patient and Donor Characteristics
N 118
Diagnosis
AML 29
ALL 24
CML 39
MDS 14
Other hematological malignancy 12
Reason for DLI
Hematologic relapse 44
Cytogenetic/molecular relapse 52
Other causes 22
Sex (M/F) 68/50
Age 37 (3-63)
Donors:
HLA-identical siblings 58
Major HLA-Ag MM, unrelated 5
Matched, unrelated 44
Allele MM, unrelated 11
Stem cell source
BM/PBSC 64/54
Conditioning
TBI+Cy 46
fTBI+Cy 23
Bu+Cy 13
Biol Blood Marrow Transplant 16:1728-1737, 2010 1729Donor Lymphocyte Infusions after ASCTwith chronic myelogenous leukemia (CML), where
there has been a high response rate in comparison
with acute myelogenous leukemia (AML) and acute
lymphoblastic leukemia (ALL) [9,10]. Leukemia cell
lineage-specific chimerism analysis may allow identifi-
cation of patients with threatening relapse of ALL and
AML after ASCT several months earlier than conven-
tional methods [14,15]. This may improve the results
of DLI in patients with acute leukemia because
treatment is started at a lower tumor burden [16]. In
addition, CML patients treated with DLI because of
molecular relapse do better than those with a hemato-
logic relapse [17].
In the present study, we performed a retrospective
analysis of 118 patients with hematologic malignancies
who received DLI mainly because of relapse. Because
we have been treating patients based on molecular
relapse from the beginning of the last decade if at all
possible, we wanted to evaluate the clinical impact of
this approach.RIC 36
GVHD prophylaxis
CsA + MTX 109
CsA + MMF 3
TCD 6
Number of DLIs per patient
One 44
Two or more 74
Bulk DLI 34
Escalating DLI 84
AML indicates acutemyelogenous leukemia; ALL, acute lymphocytic leu-
kemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syn-
drome; DLI, donor lymphocyte infusion; M, male; F, female; MM,
mismatch; BM, bone marrow; PBSC, peripheral blood stem cells; FTBI,
fractionated total body irradiation; Cy, cyclophosphamide; Bu, busulfan;
RIC, reduced-intensity conditioning; GVHD, graft-versus-host disease;
CsA, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil;
TCD, T cell depletion.MATERIAL AND METHODS
Patients and Donors
In total, 118 consecutive patientswho receivedDLI
at the Karolinska University Hospital, Huddinge, be-
tween April 1991 and September 2005, were included
in the study. The main indication for DLI treatment
was relapse of the underlying hematologic malignancy
after ASCT.Ninety-six patients were treated for either
morphologic relapse (n 5 44) or for cytogenetic/mo-
lecular relapse (n 5 52). Twenty-two patients were
treated for other reasons: 4 because of Epstein-Barr
virus (EBV) lymphoma, 7 with threatening rejection,
4 with extramedullary relapse, and 7 received DLI as
prophylactic treatment because of high-risk leukemia.
Median interval between ASCT and first dose of DLI
was 212 (24-4800) days. All patients and donors were
typed using PCR-SSP high-resolution typing for
bothHLA class I and II alleles [18]. Apart frompatients
with HLA-identical related donors (n5 58) and unre-
lated donors matched for HLA-A, -B, and -DRb1
(n 5 44), 11 patients with allele-mismatched donors
were included. Five patients received an HLA-A, -B,
and -DRb1 major antigen mismatched graft. Patient
and donor characteristics are summarized in Table 1.
The study was approved by the ethics committee at
Karolinska Institutet, Huddinge University Hospital
in Stockholm (DNR 425/97).
Conditioning and GVHD Prophylaxis
The myeloablative conditioning regimens con-
sisted of intravenous (i.v.) cyclophosphamide (60 mg/
kg daily) for 2 consecutive days in combination with
either 3 Gy of fractionated total body irradiation
(fTBI) for 4 consecutive days, or busulfan (Bu) at 4mg/kg/day for 4 days (Table 1) [19]. Cyclophospha-
mide (60 mg/kg on 2 consecutive days) combined
with 10 Gy of TBI (with the lungs shielded to receive
no more than 9 Gy), was given to 46 patients.
Reduced-intensity conditioning (RIC) was given to
36 patients and in the majority of patients it consisted
of fludarabine (30 mg/m2 for 6 days) in combination
with oral Bu (total dose 8 mg/kg) as previously de-
scribed [20]. All patients with unrelated donors
received antithymocyte-globulin (ATG) (Thymoglo-
bulin; Genzyme, Cambridge, MN, USA) for 3-5 days
before transplant, with a total dose of 6-8 mg/kg [21].
The majority of patients (n5 109) received cyclospor-
ine A (CsA) combined with 4 doses of methotrexate
(MTX) as prophylaxis against GVHD [22]. During
the first month, blood CsA levels were kept at
100-150 ng/mL in patients with sibling donors and
200-300 ng/mL in patients with a matched unrelated
donor (MUD). In the absence of GVHD, CsA was
discontinued after 3-4 months when HLA-identical
sibling donors were used and after 6 months when
1730 Biol Blood Marrow Transplant 16:1728-1737, 2010D. Sairafi et al.unrelated donors were used. In most cases where DLI
was used as treatment for relapse, immunosuppressive
therapy was discontinued prior to the first infusion.
However, in 13 patients who received DLI for various
reasons, immunosuppressive therapy was continued.Analysis of Chimerism and BCR-ABL
DNA from donor and recipient pretransplantation
samples was extracted using standard protocols (Ma-
gNA Pure, Roche, Switzerland). To evaluate lineage-
specific chimerism, CD3, CD19, and CD33-positive
cells were selected from peripheral blood using
antibody-labeledmagneticbeads (Dynal,Oslo,Norway).
Themethodology and sensitivity of chimerism analysis
in the various cell lineages has been described else-
where [14,23,24]. We have previously reported
a sensitivity of 2 1024 whenCD19-positive cells were
collected in a leukemia-affected cell-lineage specific
manner and 4  1024 for CD33-positive cells [14,15].
In all patients transplanted after 2001, chimerism
analysis was routinely performed. As part of the
posttransplantation routine, recipient samples were
collected for monitoring of chimerism status on days
114, 121, 128, and every other week up to 3
months, and then monthly thereafter. The method
of detection of BCR-ABL has been described else-
where [25,26]. Briefly, quantification was done by
competitive PCR using plasmid constructs containing
a modified BCR-ABL fusion gene. A sensitivity of 10-6
was obtained with this method after 40 cycles of PCR
amplification. Patients were monitored on a monthly
basis during the first 6 months after ASCT and then
in general after every third month. Detection with
BCR-ABL was performed in all patients with CML
and in patients with ALL expressing BCR-ABL.DLIs
Donor cells were collected by leukapheresis on 1 or
moreoccasions,dependingon the cell yield.Thirty-four
patients received a single bulk dose of fresh donor lym-
phocytes (all lymphocytes that could be collected were
given at a single time point), median 2  108 CD31
cells/kg (range: 1  106- 3.6  109 CD31 cells/kg).
The remaining patients were treated according to
a cell dose escalating protocol. Donor cells obtained
from the leukapheresis were cryopreserved with autol-
ogous plasma and DMSO. Based on an estimated cell
loss of 30% to 50% in the preservation procedure
itself, the cell doses were doubled before freezing.
The escalations in dose were done in steps of 0.5 to 1
log starting between 1  105 to 1  106 CD31 cells
per kg, depending on the type of donor, the degree
of HLAmatch, and the history of GVHD in the recip-
ient. No patients with current aGVHD were treated.
The time intervals between doses were generally 3 to5 weeks. A median dose of 1  107 CD31 cells/kg
(range: 1  105-2  108 CD31 cells/kg) was given.
Ten patients received chemotherapy prior to DLI,
all because of hematologic relapse of ALL (n 5 4), or
AML (n 5 5), or CML with blast crisis in 1 case.
Different immunosuppressive and immunostimu-
latory regimens, such as interleukin (IL)-2, were used
in conjunction with DLI as previously described, espe-
cially in the early years [27]. Briefly, 6 patients received
IL-2 alone and 8 patients were given MTX after DLI
in combination with various IL-2 regimens.
Diagnosis and Treatment of GVHD
aGVHDandcGVHDwasdiagnosedon thebasis of
clinical symptoms and/or biopsies (skin, liver, gastroin-
testinal tract, or oral mucosa) according to standard cri-
teria [28,29]. aGVHD was not restricted to any time
point after transplantation, but could appear after day
100 and at any time after DLI. The patients were
treated for grade I aGVHD using prednisolone,
starting at 2 mg/kg/day, which was tapered after the
initial response. In severe cases, ATG, methylprednis-
olone, MTX, psoralene and ultraviolet light (PUVA),
or treatment with mesenchymal stem cells was used
[30,31].
cGVHD was initially treated with CsA and ste-
roids.
Definition of Relapse, Pancytopenia, and
Rejection
Response to DLI was defined as follows: complete
response (CR) in bone marrow (BM) after hematologic
relapse, conversion to BCR-ABL-negative PCR, con-
version to full donor chimerism in relevant cell lineage,
absence of leukemic clone according to flow cytometry,
or disease remission based on cytogenetic analysis—
that is, absence of metaphases with the Philadelphia
chromosome in BM.
In this study, molecular relapse was defined as ei-
ther increasing levels of BCR-ABL, or BCR-ABL ratio
exceeding 0.02% on 3 occasions, or the ratio reaching
0.05% on 2 occasions. Molecular relapse concerning
chimerism analysis was defined as recurrence of
recipient cells in the leukemia-affected cell lineage as
described previously [14,15]. If mixed chimerism was
detected in the leukemia-affected cell lineage in periph-
eral blood in 2 consecutive samples, immunosuppres-
sion was discontinued if possible and DLI started.
The sensitivity of chimerism analysis in BM is in-
creased but specificity is lower [14]. Thus, if a patient
showed mixed chimerism in the relevant cell lineage
in BM, immunosuppression was tapered or discontin-
ued and a new BM sample was generally analysed after
1 month. If mixed chimerism was decreasing, no DLI
was given; if it continued to increase, DLI treatment
was started.
Biol Blood Marrow Transplant 16:1728-1737, 2010 1731Donor Lymphocyte Infusions after ASCTPatients were, in general, analyzed with morphol-
ogy and flow cytometry of BM aspirates at 3, 6, and
12 months, and then on an annual basis after ASCT.
All results were obtained from the Department of
Pathology, Karolinska University Hospital. A patient
with acute leukemia with regenerating peripheral
blood values was considered in clinical remission
when\5% blast cells among 200 nucleated cells were
found in a BM sample, on morphologic examination.
Clinical leukemic relapse was defined as at least 20%
blast cells in BM aspirates or the presence of extrame-
dullary leukemic cells, that is, extramedullary relapse.
Patients with myelodysplastic syndrome (MDS) were
classified according to both the FAB Cooperative
Group and the WHO classification.
Pancytopenia was defined as leukocyte counts of
\1.0  109/L, and/or platelet counts of\20  109/
L [32].Statistical Methods
The probabilities of overall survival (OS) were
estimated using the Kaplan-Meyer method and com-
pared with the log-rank test [33]. The incidence rates
of GVHD were estimated using a nonparametric
estimator of cumulative incidence curves [34]. The
competing event was death without GVHD within
100 days. Predictive analyses for GVHD were based
on the proportional hazards model for subdistribution
of competing risks. In predictive analysis for response,
the Cox regression method was used. Factors analyzed
were patient and donor age and sex, diagnosis, disease
stage, aGVHD and cGVHD, time to relapse, type of
relapse, nucleated cell dose, and conditioning.
cGVHD was analyzed as a time-dependent variable.
Analyses were performed using the cmprsk package
(developed by Gray, June 2001), Splus 6.2 software,
and Statistica software. The Mann-Whitney U-test
was used to compare continuous variables and the
Fisher exact test was used to compare the distribution
of categoric variables.RESULTS
DLI as Treatment for Hematologic Relapse
Forty-four patients were treated because of hema-
tologic relapse. Patients who received DLI treatment
because of early hematologic relapse showed a signifi-
cantly inferior survival rate compared to those with
relapse beyond 1 year after ASCT (Figure 1a). Only 3
of 24 patients (12.5%) with early hematologic relapse
responded to DLI compared to 8 of 20 patients (40%)
with relapse beyond 1 year (P5 .036).
Seven of 30 patients (23%) who did not develop
aGVHD responded after DLI treatment, compared to
4 of 11 (36%) with aGVHD of grades I-II and noneof the 3 patients with GVHD grades III-IV (ns).
However, there was a significant correlation between
development of cGVHD and a better response because
only 4 of 31 patients without cGVHDresponded, com-
pared to 7 of 13 with cGVHD (P5 .007). Six of these 7
patients had cGVHD before response.
Ten patients (9 with acute leukemia and 1 with
CML in blast crisis) with hematologic relapse received
chemotherapybeforeDLI.Only3patients showed a re-
sponse. Median survival was 112 days (range: 21-1022).
All 10 patients died: 5 because of relapse, 3 because of
GVHD, and 2 because of infection.
Furthermore, the various MTX/IL-2 regimens
had no clinical impact regarding response after DLI.
In the majority of patients with hematologic relapse
chimerism analysis was not performed because the
chimerism method was not in routine use (n 5 25).
Twelve patients had evidence of decreasing donor
chimerism before relapse but no treatment was started
because of ongoing chimerism studies. Seven patients
showed only donor chimerism before relapse but
with several months interval between last sample and
relapse.DLI Because of Mixed Chimerism in Leukemia-
Affected Cell Lineage
A total of 26 patients received DLI because of mo-
lecular relapse, defined as detection ofmixed chimerism
in the leukemia-affected cell lineage as previously
described [14,15,35]. Three patients with CML
responded to DLI, all of whom had myelogenous
mixed chimerism and all whom were BCR-ABL posi-
tive. Two patients with B cell chronic lymphocytic leu-
kemia with mixed chimerism in the B cell lineage
responded. All DLIs given and the reason behind it, di-
agnoses, andmolecularmethod used are summarized in
Table 2.
Seven patients with ALL received DLI either be-
cause of mixed chimerism in the B cell lineage (n 5 5)
or T cell lineage (CD7 expressing T cell ALL) (n5 2)
(Figure 2). Three patients responded, all of whom had
molecular relapse at 6 months or later. Two of these
patients are still alive. One patient died because of
cGVHD more than 2 years after immunotherapy. Of
the remaining patients, UPN 779 showed decreasing
levels of remaining recipient B cells but the patient
died of GVHD. Patient UPN 981 responded initially
to chemotherapy andDLIbut relapsed 10months later.
Of the 7 patients with AML and mixed chimerism
in the myeloid cell lineage, 6 responded (Figure 3).
One patient (UPN 920) with an early molecular
relapse and delayed DLI treatment did not show any
response. In 2 patients with initial response (UPN
976 and 902), recurrence of the underlying AML was
detected again 8 and 16 months after immunotherapy.
Both died of relapse. Of the remaining 4 patients, 3 are
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Figure 1. (A) Probability of survival in patients (pts) with early or late hematologic relapse after ASCT (at\365 days or .365 days, respectively).
(B) Cumulative survival if DLI was given because of hematologic, molecular, or cytogenetic (only patients with chronic myeloid leukemia) relapse after
ASCT. (C) Probability of survival in patients with acute leukemia and myelodysplastic syndrome (MDS) if DLI was given after hematologic or molecular
relapse, the latter being ascertained mainly from chimerism analysis.
1732 Biol Blood Marrow Transplant 16:1728-1737, 2010D. Sairafi et al.still alive. One patient later developed T cell ALL, and
after receiving DLI the patient died of GVHD.
The results of DLI treatment in patients withMDS
are shown in Figure 4. All patients were diagnosed with
mixed chimerism in the myeloid cell lineage between
2.5 and 5 months after ASCT. Of the 5 patients, 4
responded. Three of them are still alive.
DLI as Treatment for BCR-ABL
and Cytogenetic Relapse
Patients with cytogenetic response (CML patients
only) showed the best survival (Figure 1b). Nine
patients with CML were treated because of high or
increasing levels of BCR-ABL and 1 patient with
ALL. Three patients with CML developed mixed chi-
merism at the same time as they became BCR-ABL
positive. Eight of these patients responded to DLI
and became BCR-ABL negative. In 2 of these patients,DLI had to be combined with imatinib to induce long-
lasting BCR-ABL negativity. Three patients died. One
of them died of hematologic relapse (the patient who
did not respond) and 2 responders died several years
later because of septic shock.
Outcome after DLI for Molecular
and Cytogenetic Relapse
The majority of patients with molecular relapse
(n 5 40) had acute leukemia or MDS (n 5 27). The
majority of these molecular relapses were based on
detection of mixed chimerism in the leukemia-
affected cell lineage as stated previously. Significantly
better survival was seen if DLI treatment was given
for molecular relapse as opposed to hematological
relapse (Figure 1c).
In patients with late molecular/cytogenetic relapse
18 of 20 (90%) responded toDLI compared to 20 of 32
Table 2. Diagnoses and Reasons for Treatment with Donor Lymphocyte Infusions
Morphologic
Relapse
(n 5 44)
Cytogenetic
Relapse
(n 5 12)
BCRABL
(n 5 10)
Mixed Chimerism
(Relapse)
(n 5 26)
Mixed Chimerism
(Rejection)
(n 5 7)
FACS
(n 5 7)
Others
(n 5 15)
CML (n 5 39) 15 12 9 3* 2 0 1
AML (n 5 29) 10 0 0 7 2 4 6
MDS (n 5 14) 7 0 0 5 2 0 0
ALL (n 5 24) 6 0 1 7 0 3 7
Other hematological malignancies (n 5 12) 6 0 0 4 1 0 1
CML indicates chronic myelogenous leukemia; AMC, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphblastic leukemia;
DLI, donor lymphocyte infusion.; EBV, Epstein-Barr virus.
Others: 4 patients with EBV lymphoma, 4 with extramedullary relapse and 7 patients receiving prophylactic DLI.
*Three patients with mixed chimerism and BCR-ABL positive at the same time point.
Biol Blood Marrow Transplant 16:1728-1737, 2010 1733Donor Lymphocyte Infusions after ASCT(63%) patients with relapse during the first year after
ASCT (P 5 .06).
Development of aGVHD or cGVHD had no
significant influence on the response toDLI in patients
with molecular/cytogenetic relapse. In patients with-
out aGVHD 16 of 24 (67%) responded to DLI treat-
ment, compared to 19 of 23 patients (83%) with
aGVHD grades I-II, and 3 of 5 patients with aGVHD
grades III-IV (ns). Eighteen of 22 patients (82%) with
cGVHD responded, compared to 20 of 30 (63%) with-
out cGVHD (P 5 .11).
Multivariate Analysis of Response
In multivariate analysis, the response to DLI was
significantly associated with nonhematologic relapse
(n 5 52, P\ .001), cGVHD (n 5 29, P 5 .005), and
late relapse (n5 38, P5 .017) (Table 3). Other factors
analyzed such as patient and donor age and sex, diag-
nosis, disease stage, aGVHD, time to relapse, type of
relapse, nucleated cell dose, and conditioning did not
show ant significant association with response to DLI.ALL
780
UPN
779
791
912
922
981
1085
Months post-
1 2 3 4 5 6 7 128 9 10 110
Figure 2. Chimerism analysis of leukemia-affected cell lineage in patients wComplications, Timing, and Causes
of Death after DLI
The overall incidences of mild-to-moderate
aGVHD (grades I-II) and severe aGVHD (grades
III-IV) in thepresent studywere34%and8.5%, respec-
tively.Univariate analysis for factors affecting incidence
of aGVHD of grades II-IV showed a slight positive
effect of unrelated donors (P 5 .07) and a tendency of
a lower incidence in patients with hematologic relapse
(P5 .06).Noneof these factors showed any significance
in multivariate analysis, however. Seven of 44 (16%)
patients with hematologic relapse developed aGVHD
grades II-IV compared to 14 of 40 (35%) patients
with molecular relapse (P5 .08).
cGVHD was diagnosed in 39 of the 118 patients
(33%). Nineteen patients had mild cGVHD, 17 mod-
erate, and 3 developed severe cGVHD. The incidence
of cGVHD was more common if DLI was given .12
months after ASCT. Twenty-one of 79 patients (27%)
who were treated with DLI\12 months after ASCT
were diagnosed as having cGVHD, compared to 18R= Relapse
= CsA withdrawal
gI-gIV= GVHD grade I-IV
CR= Complete Remission
BM= Bone marrow sample
CD19+
CD34+
DC
MC 1-5%
MC 5-20%
MC >20%
SCT
ith acute lymphoblastic leukemia (ALL) who received DLI after ASCT.
UPN
R= Relapse
AML
859 = CsA withdrawal
gI-gIV= GVHD grade I-IV
CR= Complete Remission
883
902
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CD34+
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Figure 3. Chimerism analysis of leukemia-affected cell lineage in patients with acute myelogenous leukemia (AML) who received DLI after ASCT.
1734 Biol Blood Marrow Transplant 16:1728-1737, 2010D. Sairafi et al.of 39 patients (46%) who were treated with DLI be-
yond 1 year (P 5 .04).
In this study, DLI administered as a bulk-dose reg-
imen (BDR) was not associated with a higher incidence
of aGVHD grades III-IV compared to escalating-dose
regimens (EDR): 8.8% and 8.3%, respectively.
Three patients in this study developed pancytope-
nia after DLI. Two of them later rejected their grafts,
and the third patient died of relapse. All 3 patients
showedmixed chimerismof 20% to 30% recipient cells
in the myeloid and CD341 cell lineage before DLI.
Ten other patients developed isolated thrombocytope-
nia, defined as\10  109/L, 8 of whom had a fast,UPN
MDS
876
914
940
942
1030
1046
1073
Months po
1 2 3 4 5 6 7 128 9 10 110
Figure 4. Chimerism analysis of leukemia-affected cell lineage in patients with
876 and 914, DLI was given after hematologic relapse.spontaneous recovery. Because few patients developed
cytopenia after DLI, no difference between hemato-
logic relapse and cytogenetic/molecular relapse could
be detected.
Time between ASCT and the start of DLI treat-
ment did not significantly influence the risk of develop-
ing aGVHD. Of the 28 patients who received DLI
beforeday100, only 4 (14%)developed aGVHDgrades
III-IV and 13 (46%) aGVHDgrades I-II. In 10 of these
28 patients, immunosuppressive treatment was still
given because of fear of aGVHD. For patients with
DLI treatment between day 100 and day 365 (n 5
51), 15 (29%) developed aGVHD grades I-II and onlyR= Relapse
= CsA withdrawal
gI gIV GVHD grade I IV
CR= Complete Remission
- = -
BM= Bone marrow sample
CD33+
DC
MC 1-5%
CD34+
MC 5-20%
MC >20%
st-SCT BM
myelodysplastic syndrome (MDS) who received DLI after ASCT. In UPN
Biol Blood Marrow Transplant 16:1728-1737, 2010 1735Donor Lymphocyte Infusions after ASCT4 (8%) developed severe GVHD. Beyond 1 year
(n 5 39), 2 (5%) developed severe aGVHD and 12
(31%) developed aGVHD grades I-II.
Of the 118 patients included in this study, 66 died
after DLI treatment. The commonest cause of death
was relapse of the underlying malignancy (n 5 42).
Other causes of death were: GVHD (n 5 11), septic
shock (n 5 3), pneumonia (n 5 3), other infections
(n 5 3), and other causes (n 5 4).DISCUSSION
The GVL effect after ASCT is of utmost impor-
tance in the treatment of patients with leukemia. Wei-
den et al. [5] described GVL as early as in 1979, where
patients who developed GVHD had relapse rate that
was 2.5 times less than for those without it. With the
use of DLI, the GVL effect may be increased after
ASCT. Pioneering work using DLI after ASCT was
done almost 2 decades ago [36]. Increased GVL effect
in patients with leukemia may also be accomplished
by abrupt withdrawal of immunosuppression after
ASCT [37].
It has previously been shown that response to DLI
is predicted by tumor burden [27,32,38]. This is in
agreement with the findings in the present study,
where patients with hematologic relapse did significan-
tly worse than patients with cytogenetic or molecular
relapse. According to the multivariate analysis,
hematologic relapse was the strongest predictor of
poor outcome. Because of the lower efficacy of DLI
in patients with hematologic relapse, several studies
have combined DLI with chemotherapy [39,40]. In
the latter 2 studies, complete remission was achieved
in 47% and 63% patients, respectively. OS was 19%
and 31% at 2 years. In the present study, however,
the combination of chemotherapy and DLI was not
successful because none of the 10 patients survived
this therapy even though 3 patients responded.
It was previously found that DLI induces long-
lasting remission in most patients with CML, but
only in a minority of patients with acute leukemia [9].
However, as indicated in the present study, the re-
sponse may be improved if DLI is started based on
molecular monitoring of the underlying disease. Inter-
estingly, patients with acute leukemia and MDS
showed a significantly better response and OS if DLI
was started because of molecular relapse. This was, in
most cases, based on detection of recurrence of recipi-
ent cells in the leukemia-affected cell lineage. We have
previously shown that this finding is an early sign of
relapse in patients with ALL and AML [14,15]. This
is further substantiated by the fact that patients with
ALL or AML who did not respond to DLI later on
developed hematologic relapse. However, it should
be recognized that the persistence of recipient cells,especially CD33-positive cells, might be normal mye-
logenous cells and not necessarily part of the leukemic
clone. It should also be acknowledged that patients di-
agnosed directly in hematologic relapsemight have had
more aggressive diseases than those diagnosed in mo-
lecular relapse. There are several other limitations
with this study that may influence the results such as
the long time frame (1991-2005), different cells doses,
and additional use of IL-2 and MTX. However, of the
26 patients who were treated because of detection of
recipient cells in the leukemia-specific cell lineage, 20
patients responded. Interestingly, 3 of 7 with ALL
and 6 of 7 with AML responded. This is in agreement
with the findings of Bader et al. [16], that early therapy,
including rapid withdrawal of immunosuppressive
therapy and DLI, increases the response and survival
in patients with acute leukemia. The best result in the
present study was with DLI given to patients with
CML with molecular or cytogenetic relapse, which is
in accordance with the results of previous studies
[17]. Leukemia lineage-specific chimerism analysis
may reach a reasonable sensitivity to detect a threaten-
ing relapse and enable DLI at an earlier time point
[14,15]. However, PCR methods such as BCR-ABL
are preferentially used because a higher sensitivity is
achieved and the method is also disease-specific [26].
How leukemia lineage-specific chimerism analysis
compare with other methods such as flow cytometry
is currently being evaluated at our center.
Another interesting finding is that cGVHD is of
significant importance for response in patients with he-
matologic relapse, whereas it does not seem to be a ne-
cessity for patients with molecular relapse. A stronger
immunologic response is probably needed to achieve
remission in patients with a larger tumor burden. As
indicated in previous studies, the time from ASCT to
relapse also plays a role in efficacy of DLI because
patients with late relapse respond significantly better
[38]. However, the response to DLI does not appear
to be influenced by whether there is myeloablative or
reduced conditioning or whether the donor is related
or unrelated according to multivariate analysis. This
is also in agreement with a recent study by the EBMT
Acute LeukemiaWorking Party involving 399 patients
with AML [38].
According to the findings of this study, it is safe to
give DLI early after ASCT, which contrast with the
results of previous studies [13]. Few clinical studies
have been reported concerning DLI early after ASCT,
but several animal studies have shown that DLI is
much more likely to cause GVHD if given soon after
an intensive preparatory therapy [41]. Twenty-eight
patients received DLI before day 100 in this study and
only 4 developed aGVHD grades III-IV. Almost half
of the patients developed aGVHD grades I-II, but
this is desirable among these patients [4]. However, 10
of these patients were still on immunosuppressive
Table 3. Multivariate Analysis Concerning Factors Related to Response of Donor Lymphocyte Infusion (DLI)
Factor No (n) Yes (n) RR 95% CI P-value
Late relapse 58 38 2.06 1.14-3.72 .017
Nonhematologic relapse 44 52 3.36 1.69-6.68 <.001
Chronic GVHD 67 29 1.51 1.13-2.01 .005
GVHD indicates graft-versus-host disease; CI, confidence interval; RR, relative risk.
Patients who received DLI because of rejection or as prophylaxis were excluded from analysis. Concerning diagnosis, acute leukemia and MDS were
compared against all other diagnoses. Chronic GVHD is analyzed as a time-dependent variable.
1736 Biol Blood Marrow Transplant 16:1728-1737, 2010D. Sairafi et al.therapy at the time ofDLI. Themajority of patients re-
sponded to DLI despite ongoing immunosuppressive
therapy, but with poor response in patients with threat-
ening relapse. Thus, with patients in the latter category,
immunosuppressive therapy should be discontinued
before DLI is initiated.
In contrast to previous studies [32,38,42], few
patients developed severe GVHD and pancytopenia
after DLI in the present study. One explanation for
this may be that all our patients who received
unrelated donor transplants were treated with ATG
before ASCT, which is correlated to a reduced risk of
developing GVHD [21]. Pancytopenia only occurred
in 3 patients and another 10 patients developed throm-
bocytopenia, which recovered spontaneously in 8 of
them.One reason for this is that themajority of patients
received DLI treatment based on molecular methods
and chimerism analysis. If treatment with DLI is
started at hematologic relapse with a high proportion
of recipient cells, the risk of pancytopenia may be
increased [9].
We can conclude that, in contrast to what has been
reported previously, it is safe to administer DLI early
after ASCT with regard to induction of GVHD and
pancytopenia. It also appears to be beneficial when
DLI is given because of molecular relapse of acute leu-
kemias,with increased response rate and survival.These
data highlight the necessity that DLI treatment should
be based onminimal residual disease andmonitoring of
chimerism as opposed to morphologic relapse.ACKNOWLEDGMENTS
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